Cargando…
P1486: SERUM BIOMARKERS AS PREDICTORS OF RESPONSE TO SUTIMLIMAB IN COLD AGGLUTININ DISEASE (CAD): A POST-HOC ANALYSIS OF PHASE 3 CARDINAL AND CADENZA STUDY DATA
Autores principales: | Barcellini, Wilma, Broome, Catherine M, Jilma, Bernd, Ueda, Yasutaka, Vos, Josephine, D’sa, Shirley, Khan, Umer, Yoo, Ronnie, Wardęcki, Marek, Röth, Alexander |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430213/ http://dx.doi.org/10.1097/01.HS9.0000972828.06446.17 |
Ejemplares similares
-
Concomitant Use of Sutimlimab and COVID-19 Vaccines in Patients with Cold Agglutinin Disease from the Phase 3 Cardinal and Cadenza Studies
por: Fattizzo, Bruno, et al.
Publicado: (2022) -
Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial
por: Röth, Alexander, et al.
Publicado: (2022) -
P1487: CONCOMITANT USE OF SUTIMLIMAB AND COVID-19 VACCINES IN PATIENTS WITH COLD AGGLUTININ DISEASE FROM THE PHASE 3 CARDINAL AND CADENZA STUDIES
por: Fattizzo, Bruno, et al.
Publicado: (2023) -
P1469: INHIBITION OF COMPLEMENT C1S WITH SUTIMLIMAB IN PATIENTS WITH COLD AGGLUTININ DISEASE (CAD): RESULTS FOLLOWING 9-WEEK OFF-TREATMENT PERIOD (WASHOUT) IN THE PHASE 3 CADENZA STUDY
por: Röth, Alexander, et al.
Publicado: (2023) -
Long-term sutimlimab improves quality of life for patients with cold agglutinin disease: CARDINAL 2-year follow-up
por: Röth, Alexander, et al.
Publicado: (2023)